| Document |
Document Title |
|
WO/2021/125484A1 |
The present invention relates to a peptide that can be used to alleviate skin troubles caused by fine dust and inhibits the activity of an aryl hydrocarbon receptor, and a cosmetic composition using the same.
|
|
WO/2021/121068A1 |
Disclosed are a macromolecule for promoting the intake of an anticancer drug, and a composition containing same and the use thereof in the preparation of an anticancer drug. The macromolecule has multiple guanidine groups and optionally ...
|
|
WO/2021/121173A1 |
An mRNA targeting molecule based on an N-acetylgalactosamine binding polypeptide and a preparation method therefor. A plasmid vector containing a DNA fragment formed by sequentially connecting a promoter, a target gene, a specific protea...
|
|
WO/2021/123050A1 |
The present disclosure relates to the field of unconventional neurotrophic factors and to the field of treating degenerative, chronic or progressive diseases and disorders, and monogenic hereditary diseases having ER stress as a pathogen...
|
|
WO/2021/118199A2 |
The present invention provides a cosmetic composition for suppression or alleviation of seborrhea and a pharmaceutical composition for prevention, alleviation, and treatment of seborrhea, each composition comprising a specific peptide as...
|
|
WO/2021/113922A1 |
The present invention relates to an improved synthetic process for preparing N-(benzenesulfonyl)-L-prolyl-L-O-(1-pyrrolidinylcarbonyl)tyr
osine. The present invention is also directed to individual steps in this process and individual in...
|
|
WO/2021/119571A1 |
Provided herein are phosphodiesterase 4 (PDE4) inhibitors, e.g., a compound of Formula (I) or (II), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or m...
|
|
WO/2021/116679A1 |
The present invention relates to treatments of diabetic macular edema (DME) and impaired visual acuity, comprising intravitreally administering the compound of formula (A) (or a pharmaceutically acceptable salt and/or solvate thereof): F...
|
|
WO/2021/108916A1 |
Novel peptides and their uses are provided. In particular, the peptides are useful for increasing glucose uptake or decreasing hepatic glucose production. The peptides are also useful for regulating glucose levels and/or treating diabete...
|
|
WO/2021/113528A1 |
The present disclosure is concerned with dipeptide compounds for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, c...
|
|
WO/2021/112014A1 |
A problem addressed by the present invention is to provide a bronchial embolization material capable of tissue repair and replacement. This bronchial embolization material contains a protein (A), wherein: the protein (A) has a polypeptid...
|
|
WO/2021/059266A9 |
Compositions comprising specific tetrapeptides, for use in treating, preventing, minimizing, diminishing or reversing various signs of aging of the skin are provided. The compositions are useful in improving the firmness or elasticity of...
|
|
WO/2021/059267A9 |
Pharmaceutical compositions comprising specific tetrapeptides, for use in treating, preventing, minimizing, diminishing or reversing degenerative, age-related and trauma- induced disorders, particularly of the eye, are provided.
|
|
WO/2021/107316A1 |
The present invention relates to peptides inhibiting androgen receptor activity, and a cosmetics composition using same that can be used to alleviate androgen-related diseases such as prostate cancer, skin diseases, alopecia, and the like.
|
|
WO/2021/106000A1 |
The invention provides a method of preparing a biaryl-bridged cyclic peptide compound of Formula (I), where R1, R2, R3, R4, R5, R8, R7, R8, R9, R10, R11, R12, n and m are as defined in the specification. The biaryl-bridged cyclic peptide...
|
|
WO/2021/100614A1 |
The present invention relates to: a neuropsychological function improver which contains, as an active ingredient, a dipeptide containing proline or a tripeptide containing glycine and proline; and a neuropsychological function improver w...
|
|
WO/2021/097980A1 |
Disclosed are a caspase-3 inhibitor and the use thereof. The caspase-3 inhibitor comprises two molecule forms, the core function regions thereof are respectively DMPD (aspartic acid-methionine-proline-aspartic acid) and DMLD (aspartic ac...
|
|
WO/2021/099659A1 |
The invention relates to peptides of general formula S, wherein the carboxyl terminus (D-alanine, D-Ala) is replaced by an analogous amino alcohol. The invention also relates to the method for synthesising same and the use of the aforeme...
|
|
WO/2021/093374A1 |
A method for synthesizing an argatroban hydrate. A compound I argatroban monohydrate is obtained by using a compound II as a starting material and an organosilane compound as a reducing agent under the catalytic reduction of an organic a...
|
|
WO/2021/093695A1 |
Provided herein are a polypeptide compound, a pharmaceutical composition, and a preparation method and use thereof. The structural formula of the polypeptide compound is shown in general formula (I). Such polypeptide compounds as k-opioi...
|
|
WO/2021/090894A1 |
The present invention addresses the problem of providing a novel peptide capable of treating, preventing, or ameliorating a mood disorder. The present invention provides a peptide that has an amino acid sequence set forth in SEQ ID NO:...
|
|
WO/2021/091956A1 |
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
|
|
WO/2021/090855A1 |
The following were discovered: a cyclic peptide compound that interacts with Ras; and an unnatural amino acid that is useful in the production of said cyclic peptide compound. The cyclic peptide compound was also discovered to inhibit bo...
|
|
WO/2021/091967A1 |
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
|
|
WO/2021/091982A1 |
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
|
|
WO/2021/087268A1 |
Disclosed is a composition and method for a therapeutic treatment that is able to combat certain conditions such as addiction, alcohol dependence, opioid abuse treatment, neurological disorders, neuropathic pain, and combinations thereof...
|
|
WO/2021/082311A1 |
Provided in the present invention are a pea peptide having a supplementary blood glucose reducing function, and a preparation method and a use therefor. The components of the pea peptide at least comprise the peptides pEE, pEK, and pER, ...
|
|
WO/2021/081619A1 |
A skin and/or hair care composition includes a mixture of low-molecular weight hemp (LMWH) peptides, some or all of the peptides are less than about 1 kDa in size. The composition may be a nutraceutical, food product, beverage or topical...
|
|
WO/2021/082310A1 |
A rice peptide having a whitening function, and preparation method and a use therefor. The components of the rice peptide at least comprise the peptides GS, GL, and GF. On the basis of the quality of the rice peptide, the content of the ...
|
|
WO/2021/087084A1 |
Small molecule compounds and corresponding dimers having inhibitory activity against pre-miR-21 RNA and related methods for treatment of neoplastic disease such as cancer and especially cancers expressing miR-21 are disclosed.
|
|
WO/2021/084665A1 |
An agent effective in promoting production of PDGF-BB, and an agent which, using that agent, is effective for activation and anti-aging of the skin through stabilization of mesenchymal stem cells in the skin are provided. The PDGF-BB pro...
|
|
WO/2021/086892A1 |
Disclosed herein are methods of treating Rett syndrome comprising administering trofinetide to a subject in need thereof in which a dosage is provided that may reduce or avoid underexposure, e.g., in low body weight subjects, and/or prov...
|
|
WO/2021/077317A1 |
Provided are an oligopeptide linker intermediate and a preparation method therefor. The method has mild reaction conditions, almost no side reaction, few impurities, and the product is relatively pure and easy to purify.
|
|
WO/2021/079380A1 |
The present invention relates to improved process for the preparation of (2S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)-
amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridi
n-3-yl)-5-oxopyrrolidine-2-carboxamide and...
|
|
WO/2021/079987A1 |
The present invention relates to a muscle quality improvement agent that contains a γ-glutamyl peptide. This invention makes it possible to provide a muscle quality improvement agent that can prevent a decrease in muscle quality or impr...
|
|
WO/2021/081023A1 |
The present invention provides supramolecular filament and/or sphere compositions and their use as inhalable drug carriers within aerosols. The invention provides insights into peptide designs and supramolecular stability and its crucial...
|
|
WO/2021/075707A1 |
The present invention relates to a method for preparing a silk-derived peptide. A silk-derived peptide preparation method according to the present invention can comprise: a dissolution step of dissolving silk fibroin; a step of treating ...
|
|
WO/2021/077010A1 |
Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Linda...
|
|
WO/2021/075792A1 |
The present invention relates to a peptide composition, and may particularly be a cosmetic composition and a pharmaceutical composition that exhibit an effect of improving scalp health and preventing, alleviating, or treating hair loss. ...
|
|
WO/2021/076710A1 |
N-Acylated histidine dipeptides of formula are disclosed (I). The compounds are useful for treating breast cancer.
|
|
WO/2021/076902A1 |
Disclosed are small molecule antagonists of human α4β 7 integrin, and methods of using them to treat a number of diseases and conditions.
|
|
WO/2021/074647A1 |
The present invention relates to a method of treating cancer in a subject.
|
|
WO/2021/068080A1 |
Described herein is an immunogenic fusion protein comprising: an immunogenic peptide or an immunogenic variant thereof, the immunogenic peptide comprising the following motifs: - KQPAa; QPAKa; PAKQa; or AKQPa; - NPDPb; PNPDb; DPNPb; or P...
|
|
WO/2021/070920A1 |
A cyclic peptide that has a cyclic structure consisting of 4-30 amino acids or derivative(s) thereof, or a pharmaceutically acceptable salt thereof. In the cyclic structure, the cyclic peptide contains at least carboranylalanine(Cba) and...
|
|
WO/2021/070083A1 |
Compositions for making native-like marine structures are provided. The compositions include materials, typically a limestone and/or ceramic composite, for 3D printing of marine structures. Environmentally-friendly 3D printing and coatin...
|
|
WO/2021/072212A1 |
In some embodiments, the present disclosure provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula (II) as describ...
|
|
WO/2021/070696A1 |
The present invention provides a cyclic peptide that has, in a ring, an amino acid sequence represented by formula (I): X1-His-Pro-X4-Leu-X6-X7-X8-Ser-X10-His-Phe (where X1, X4, X6, X7, X8, and X10 each independently represent an arbitra...
|
|
WO/2021/064593A1 |
The present invention relates to novel linear ultrashort lipopeptides, pharmaceutical and cosmetic compositions comprising lipopeptides, and lipopeptides for use as drugs in treatment of bacterial infections.
|
|
WO/2021/064361A1 |
The invention relates to the detection of EGYR peptide in a biological sample as a measure of the presence and/or amount of LARP1 protein in the sample. Suitably, the invention relates to methods for quantitative measurement of LARP1 and...
|
|
WO/2021/067460A1 |
The disclosure provides cryptophycin intermediates, cryptophycin analogs, and cryptophycin chimeric molecules useful in treating cancer, as well as methods of producing these compounds and methods of treating cancer.
|
